PEAK6 Investments LLC Has $374,000 Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

PEAK6 Investments LLC reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 32.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,400 shares of the company’s stock after selling 5,000 shares during the period. PEAK6 Investments LLC’s holdings in Dyne Therapeutics were worth $374,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. FORA Capital LLC lifted its position in Dyne Therapeutics by 121.1% during the third quarter. FORA Capital LLC now owns 18,180 shares of the company’s stock worth $653,000 after acquiring an additional 9,958 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics during the third quarter worth approximately $34,000. Advantage Alpha Capital Partners LP acquired a new stake in Dyne Therapeutics during the third quarter worth approximately $386,000. FMR LLC lifted its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Dyne Therapeutics during the third quarter worth approximately $430,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DYN has been the subject of several research reports. Piper Sandler restated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $29.44 on Thursday. The company’s 50 day simple moving average is $31.45 and its 200 day simple moving average is $35.49. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -8.27 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $10.33 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 176,257 shares of company stock valued at $6,193,718. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.